Company Profile - Nymox Pharmaceutical Corp

Introduction

Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that develops therapeutics in the area of male health and diagnostic products. It is developing a drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH) and early-stage prostate cancer. The company markets diagnostic products for measuring tobacco product exposure and for the diagnosis of Alzheimer’s disease. Its diagnostic product portfolio includes N9icAlert test to determine smoking status; and TobacAlert home test to determine a person’s level of exposure to tobacco products, including secondhand smoke. Nymox’s lead drug candidate, NX-1207 is intended for the treatment of BPH and for early-stage prostate cancer. The company markets and distributes its products across North America, Asia, and Europe through its own marketing and distribution centers and medical representatives. Nymox is headquartered in Saint Laurent, Quebec, Canada.